Around 20% of all breast cancers have amplification of the human epidermal growth factor receptor 2 (HER2), which had been associated with aggressive tumour type and poor prognosis, before targeted therapies for HER2 were developed [1–4]. Here, ERBB2 is linked to neoplasm.